Protea Biosciences to Develop GWU's LAESI MS Technology for Research Laboratories | GenomeWeb

Protea Biosciences announced this week that it has concluded an exclusive, worldwide license agreement with George Washington University for commercial rights to a new mass spectrometry technology for in situ tissue and cell analysis called laser ablation electrospray analysis, or LAESI.

In a statement, Protea said it will develop instrumentation and software "that will bring the capabilities of the LAESI technology to research laboratories worldwide, beginning in 2011."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.